Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Gocatamig · MK-6070, HPN328

Bispecific antibody (Multispecific) · Immune activation, directed at CD3 epsilon (CD3E) and delta-like protein 3 (DLL3) · developed by Merck &

Phase 1/2 Most advanced trial

MRK Developer

1 Registered trials

What is Gocatamig?

Gocatamig is a tri-specific antibody construct that binds CD3 on T cells and DLL3 on tumor cells, bringing them together to trigger T-cell-mediated killing of DLL3-expressing cancer cells. An albumin-binding domain extends its serum half-life. It is studied in small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: MK-6070, HPN328, DS-3280
Drug type: Bispecific antibody (Multispecific)
Targets: CD3 epsilon (CD3E), delta-like protein 3 (DLL3), human serum albumin (ALB) (binding partner it blocks)
Mechanism: Immune activation, directed at CD3 epsilon (CD3E) and delta-like protein 3 (DLL3)
Pathways: Notch signaling
Therapy area: Oncology
Developer: Merck & Co. (MRK)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: U6CKL88C8H

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07227597	Phase 1/2	Small Cell Lung Cancer Extensive Stage	Recruiting	MRK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Small Cell Lung Cancer Extensive Stage

Other drugs acting on CD3E / DLL3

Anti-Thymocyte Globulin FDA approved Blinatumomab FDA approved Tarlatamab FDA approved AZD5492 Phase 1/2 CT-95 Phase 1 Foralumab Phase 2 Imvotamab Phase 1/2 Mipletamig Phase 1 MK-1045 Phase 2/3 Odronextamab Phase 2/3 TAK-186 Phase 1/2

More from Merck &

BCG Live FDA approved Belzutifan FDA approved Berahyaluronidase Alfa FDA approved Berahyaluronidase Alfa and Pembrolizumab FDA approved Enlicitide FDA approved Ensifentrine FDA approved Letermovir FDA approved Pembrolizumab FDA approved Probenecid FDA approved Alimatravir Phase 2 Bomedemstat Phase 2/3 Calderasib Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the MRK page.

Follow MRK, the company behind Gocatamig

See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MRK catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z